BPOM Detects Novel Chemical Adulterant Pyrimidenafil in Herbal Supplements Signaling Evolving Illicit Manufacturing Tactics

The Indonesian Food and Drug Authority, known locally as Badan Pengawas Obat dan Makanan (BPOM), has identified a significant and concerning development in the illicit manufacturing of traditional herbal medicines, or Obat Bahan Alam (OBA). In a recent regulatory sweep, the agency discovered the presence of pyrimidenafil, a chemical substance never before documented in the context of Indonesian herbal product monitoring. This discovery represents a strategic shift by illicit manufacturers aiming to circumvent established testing protocols and evade regulatory detection.

The Emergence of Pyrimidenafil: A New Regulatory Challenge

Pyrimidenafil is a synthetic chemical compound that functions as a phosphodiesterase-5 (PDE5) inhibitor. This mechanism of action is functionally identical to well-known prescription medications used to treat erectile dysfunction, such as sildenafil and tadalafil. By inhibiting the PDE5 enzyme, the substance facilitates increased blood flow, which artificially simulates sexual performance enhancements.

The identification of this specific compound occurred during intensive laboratory analysis of products marketed as stamina enhancers. Three specific brands—EXIE, YUBOKKI, and DURAMAX—were found to contain the unauthorized chemical. All three products were manufactured by PT Bintang Kupu-Kupu, a firm based in Tangerang. The detection of pyrimidenafil is being treated as a high-priority case by BPOM, as it highlights a sophisticated effort by producers to mask their activities. By utilizing chemical analogs that differ structurally from traditional adulterants like sildenafil, manufacturers hope to bypass the standard screening arrays employed by state laboratories.

Evolution of Modus Operandi in Herbal Adulteration

For years, the illegal addition of Bahan Kimia Obat (BKO)—or "Medicinal Chemical Substances"—to herbal products has been a persistent public health challenge in Indonesia. Traditionally, unscrupulous manufacturers added potent pharmaceuticals like sildenafil, tadalafil, sibutramine (a weight-loss aid), or corticosteroids like dexamethasone to herbal formulations to provide consumers with an immediate, albeit dangerous, "effect."

However, the discovery of pyrimidenafil suggests a tactical evolution. BPOM head Taruna Ikrar emphasized that the use of a novel, lesser-known chemical compound is a deliberate attempt to deceive authorities. As regulatory bodies like BPOM refine their analytical methods to detect common adulterants, illicit actors are searching for "niche" chemicals that may not be included in standard rapid-testing panels. This "cat-and-mouse" dynamic forces regulatory agencies to constantly invest in advanced mass spectrometry and high-performance liquid chromatography (HPLC) techniques to maintain oversight.

Regulatory Chronology and Enforcement Actions

The discovery of pyrimidenafil was part of a broader, sustained enforcement campaign conducted throughout July 2026. This period saw a significant spike in the identification of sub-standard and dangerous products.

• Initial Detection: Through routine market surveillance and tip-offs, BPOM expanded its analytical testing to include emerging chemical analogs.
• Identification of Three Brands: Laboratory results confirmed the presence of pyrimidenafil in EXIE, YUBOKKI, and DURAMAX, leading to immediate administrative action.
• Product Recalls and License Revocation: BPOM has officially revoked the distribution licenses for these three specific products. Furthermore, the agency has initiated legal proceedings against the manufacturer, PT Bintang Kupu-Kupu.
• The Wider Sweep: Beyond the pyrimidenafil-laced products, BPOM reported the seizure of 35 additional items categorized as "Without Distribution Permit" (Tanpa Izin Edar/TIE). These products were found to contain a cocktail of other dangerous substances, including sibutramine, sildenafil, and paracetamol, which are frequently hidden in products marketed as "herbal" cures for everything from obesity to chronic aches and pains.

The Broader Impact on Public Health

The presence of unlisted chemical substances in herbal products poses severe risks to the Indonesian public. Consumers who purchase these products often do so under the impression that they are consuming natural, safe ingredients. Because these chemical additions are not disclosed on the label, consumers are at risk of drug-to-drug interactions, severe allergic reactions, and cardiovascular complications.

For instance, PDE5 inhibitors like pyrimidenafil can be life-threatening when taken by individuals with underlying heart conditions or those currently prescribed nitrate-based medications. The unpredictability of dosage in illicitly manufactured products—where one pill might contain a lethal dose while another contains none—further exacerbates the danger.

Institutional Response and Technical Upgrades

In response to these findings, BPOM has announced an intensification of its laboratory capacity. Recognizing that the industry of illegal drug manufacturing is becoming more technically adept, the agency is taking three specific steps to mitigate future risks:

1. Methodological Expansion: The agency is actively developing and validating new analytical methods capable of identifying a wider range of drug analogs and chemical derivatives.
2. Expanded Surveillance: BPOM is increasing the frequency of sampling for products that make "instant result" claims, particularly those marketed for stamina, weight loss, and pain management.
3. Enhanced Inter-Agency Cooperation: BPOM is working closely with law enforcement and the judiciary to ensure that manufacturers found guilty of adulteration face penalties that serve as a genuine deterrent, rather than merely a cost of doing business.

Consumer Vigilance: A Necessary Defense

While BPOM continues to upgrade its surveillance, the agency stresses that consumer awareness remains the first line of defense. The market for "miracle" herbal products is fueled by the demand for instant relief. BPOM officials are urging the public to be deeply skeptical of any product that promises immediate physical transformations, whether it be rapid weight loss or near-instantaneous stamina enhancement.

The agency has provided a checklist for consumers to navigate the current market safely:

• Verification: Utilize the official BPOM mobile application or website to verify the registration number of any herbal product.
• Label Scrutiny: Be wary of packaging that lacks a clear list of ingredients or contains excessive, hyperbolic claims.
• Sourcing: Purchase health products only from reputable, licensed pharmacies or verified retailers. Avoid buying "miracle" supplements from unregulated online marketplaces or social media vendors where traceability is non-existent.

The Future of Herbal Regulation

The case of pyrimidenafil marks a turning point in the regulation of herbal products in Indonesia. It serves as a reminder that the global trade in counterfeit and adulterated medicines is becoming increasingly sophisticated. As the pharmaceutical industry advances, so too does the black market, which now has access to precursors and chemical analogs through global supply chains.

The regulatory implications are clear: the era of static testing—where agencies only test for a fixed list of common additives—is ending. Future oversight will require a dynamic, intelligence-led approach that monitors international chemical trends and adjusts testing protocols in real-time. BPOM’s success in isolating pyrimidenafil is a testament to the agency’s growing technical expertise, yet it also highlights the magnitude of the challenge ahead. The continued prevalence of 35 other unauthorized products containing known banned substances serves as a sobering reminder that while one loophole has been identified and closed, the structural problems within the illicit herbal supplement market remain profound and require sustained national attention.